1. Home
  2. PSTX
  3. PSTX News

Latest Poseida Therapeutics Inc. (PSTX) News on October 23, 2024

PSTX

MT Newswires

6 days ago

Poseida Nominates New CAR-T Development Candidate, Triggering $15 Million Milestone Payment

Poseida Therapeutics Announces Nomination of New CAR-T Development Candidate Under Collaboration with Roche
PSTX

PR Newswire

6 days ago

Poseida Therapeutics Announces Nomination of New CAR-T Development Candidate Under Collaboration with Roche

MaxCyte Appoints Cynthia Collins to its Board of Directors
PSTX

GlobeNewswire

8 days ago

MaxCyte Appoints Cynthia Collins to its Board of Directors

Poseida Therapeutics Named to Newsweek's List of the Top 200 America's Most Loved Workplaces for 2024
PSTX

PR Newswire

20 days ago

Poseida Therapeutics Named to Newsweek's List of the Top 200 America's Most Loved Workplaces for 2024

PSTX

MT Newswires

a month ago

Poseida Therapeutics Study of Prospective Myeloma Treatment Yields Positive Data

Poseida Therapeutics Reports Positive Interim Phase 1 Results for Allogeneic CAR-T Therapy P-BCMA-ALLO1 with High Overall Response Rates in Heavily Pretreated Relapsed/Refractory Multiple Myeloma Patients
PSTX

PR Newswire

a month ago

Poseida Therapeutics Reports Positive Interim Phase 1 Results for Allogeneic CAR-T Therapy P-BCMA-ALLO1 with High Overall Response Rates in Heavily Pretreated Relapsed/Refractory Multiple Myeloma Patients

FDA grants RMAT to Poseida’s CAR-T cell therapy P-BCMA-ALLO1
PSTX

Pharmaceutical Technology

a month ago

FDA grants RMAT to Poseida’s CAR-T cell therapy P-BCMA-ALLO1

PSTX

MT Newswires

a month ago

Poseida Gets Regenerative Medicine Advanced Therapy Designation for Myeloma Treatment; Shares Rise

Poseida Therapeutics Receives Regenerative Medicine Advanced Therapy (RMAT) Designation from FDA for P-BCMA-ALLO1 to Treat Relapsed/Refractory Multiple Myeloma
PSTX

PR Newswire

a month ago

Poseida Therapeutics Receives Regenerative Medicine Advanced Therapy (RMAT) Designation from FDA for P-BCMA-ALLO1 to Treat Relapsed/Refractory Multiple Myeloma

Poseida Therapeutics to Present New Clinical Data from Phase 1 Study of Allogeneic CAR-T P-BCMA-ALLO1 in Patients with Relapsed/Refractory Multiple Myeloma at 21st International Myeloma Society Annual Meeting
PSTX

PR Newswire

2 months ago

Poseida Therapeutics to Present New Clinical Data from Phase 1 Study of Allogeneic CAR-T P-BCMA-ALLO1 in Patients with Relapsed/Refractory Multiple Myeloma at 21st International Myeloma Society Annual Meeting

Poseida Therapeutics Presents New Case Study Demonstrating Reactivation of CAR-T Therapy with a T-Cell Engager in a Patient with Relapsed Multiple Myeloma
PSTX

PR Newswire

2 months ago

Poseida Therapeutics Presents New Case Study Demonstrating Reactivation of CAR-T Therapy with a T-Cell Engager in a Patient with Relapsed Multiple Myeloma

Poseida Therapeutics to Present at Upcoming Investor Conferences
PSTX

PR Newswire

2 months ago

Poseida Therapeutics to Present at Upcoming Investor Conferences

Poseida Therapeutics Second Quarter 2024 Earnings: Beats Expectations
PSTX

Simply Wall St.

3 months ago

Poseida Therapeutics Second Quarter 2024 Earnings: Beats Expectations

Poseida Therapeutics, Inc. (PSTX) Reports Q2 Loss, Tops Revenue Estimates
PSTX

Zacks

3 months ago

Poseida Therapeutics, Inc. (PSTX) Reports Q2 Loss, Tops Revenue Estimates

Poseida Therapeutics Provides Updates and Financial Results for the Second Quarter of 2024
PSTX

PR Newswire

3 months ago

Poseida Therapeutics Provides Updates and Financial Results for the Second Quarter of 2024

Poseida Therapeutics, Inc.'s (NASDAQ:PSTX) institutional investors lost 22% over the past week but have profited from longer-term gains
PSTX

Simply Wall St.

3 months ago

Poseida Therapeutics, Inc.'s (NASDAQ:PSTX) institutional investors lost 22% over the past week but have profited from longer-term gains

Are You Looking for a Top Momentum Pick? Why Poseida Therapeutics, Inc. (PSTX) is a Great Choice
PSTX

Zacks

3 months ago

Are You Looking for a Top Momentum Pick? Why Poseida Therapeutics, Inc. (PSTX) is a Great Choice

Poseida Therapeutics Announces Participation in Stifel's 2024 Virtual Cell Therapy Forum
PSTX

PR Newswire

4 months ago

Poseida Therapeutics Announces Participation in Stifel's 2024 Virtual Cell Therapy Forum

BigBear.ai Stock: Buy, Sell, or Hold?
PSTX

Motley Fool

4 months ago

BigBear.ai Stock: Buy, Sell, or Hold?

Indonesia's first Olympic gymnast encourages others to 'dream higher'
PSTX

AFP

4 months ago

Indonesia's first Olympic gymnast encourages others to 'dream higher'

Where Will CrowdStrike Stock Be in 1 Year?
PSTX

Motley Fool

4 months ago

Where Will CrowdStrike Stock Be in 1 Year?

Warren Buffett's Strategic Acquisition in Occidental Petroleum Corp
PSTX

GuruFocus.com

4 months ago

Warren Buffett's Strategic Acquisition in Occidental Petroleum Corp

Insider Sale: EVP, CEO of Patient Direct, Perry Bernocchi, Sells Shares of Owens & Minor ...
PSTX

GuruFocus.com

4 months ago

Insider Sale: EVP, CEO of Patient Direct, Perry Bernocchi, Sells Shares of Owens & Minor ...

A Look At The Intrinsic Value Of Deufol SE (HMSE:DE1)
PSTX

Simply Wall St.

4 months ago

A Look At The Intrinsic Value Of Deufol SE (HMSE:DE1)

Chemring Group First Half 2024 Earnings: EPS: UK£0.045 (vs UK£0.067 in 1H 2023)
PSTX

Simply Wall St.

4 months ago

Chemring Group First Half 2024 Earnings: EPS: UK£0.045 (vs UK£0.067 in 1H 2023)

VanEck Semiconductor ETF Is Riskier Than You Think
PSTX

Motley Fool

4 months ago

VanEck Semiconductor ETF Is Riskier Than You Think

Poseida Therapeutics Announces Virtual 2024 Annual Meeting of Stockholders
PSTX

PR Newswire

5 months ago

Poseida Therapeutics Announces Virtual 2024 Annual Meeting of Stockholders

PSTX

MT Newswires

5 months ago

Poseida Therapeutics Q1 Net Loss Narrows, Revenue Rises

Poseida Therapeutics Provides Updates and Financial Results for the First Quarter of 2024
PSTX

PR Newswire

5 months ago

Poseida Therapeutics Provides Updates and Financial Results for the First Quarter of 2024

Poseida Highlights Strong Progress on Its Genetic Medicine Programs at the American Society for Gene and Cell Therapy 27th Annual Meeting
PSTX

PR Newswire

5 months ago

Poseida Highlights Strong Progress on Its Genetic Medicine Programs at the American Society for Gene and Cell Therapy 27th Annual Meeting

Broker Revenue Forecasts For Poseida Therapeutics, Inc. (NASDAQ:PSTX) Are Surging Higher
PSTX

Simply Wall St.

6 months ago

Broker Revenue Forecasts For Poseida Therapeutics, Inc. (NASDAQ:PSTX) Are Surging Higher

Xyphos and Poseida to develop allogeneic cell therapies for cancer
PSTX

Pharmaceutical Technology

6 months ago

Xyphos and Poseida to develop allogeneic cell therapies for cancer

PSTX

MT Newswires

6 months ago

Poseida Therapeutics to Receive Up to $600 Million in Cancer Gene Therapy Research, Development Deal With Xyphos

Astellas and Poseida Therapeutics Enter Into Research Collaboration and License Agreement to Develop Novel Allogeneic Cell Therapies in Oncology
PSTX

PR Newswire

6 months ago

Astellas and Poseida Therapeutics Enter Into Research Collaboration and License Agreement to Develop Novel Allogeneic Cell Therapies in Oncology

Astellas and Poseida Therapeutics Enter Into Research Collaboration and License Agreement to Develop Novel Allogeneic Cell Therapies in Oncology
PSTX

PR Newswire

6 months ago

Astellas and Poseida Therapeutics Enter Into Research Collaboration and License Agreement to Develop Novel Allogeneic Cell Therapies in Oncology

Astellas adds to ‘off-the-shelf’ cell therapy capabilities with Poseida deal
PSTX

BioPharma Dive

6 months ago

Astellas adds to ‘off-the-shelf’ cell therapy capabilities with Poseida deal

Poseida Therapeutics Announces Strong Lineup of Presentations at the American Society of Gene and Cell Therapy 27th Annual Meeting
PSTX

PR Newswire

6 months ago

Poseida Therapeutics Announces Strong Lineup of Presentations at the American Society of Gene and Cell Therapy 27th Annual Meeting

Poseida Therapeutics Hosts Gene Therapy R&D Day Highlighting New Scientific Advancements and Pipeline Focus
PSTX

PR Newswire

6 months ago

Poseida Therapeutics Hosts Gene Therapy R&D Day Highlighting New Scientific Advancements and Pipeline Focus

Poseida Therapeutics Presents New Phase 1 Data at AACR 2024 Supporting Potential of P-BCMA-ALLO1 Allogeneic CAR-T Therapy to Benefit Broad Range of Patients with Multiple Myeloma
PSTX

PR Newswire

6 months ago

Poseida Therapeutics Presents New Phase 1 Data at AACR 2024 Supporting Potential of P-BCMA-ALLO1 Allogeneic CAR-T Therapy to Benefit Broad Range of Patients with Multiple Myeloma

Poseida Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
PSTX

PR Newswire

7 months ago

Poseida Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Poseida Therapeutics Appoints Syed Rizvi, M.D., as Chief Medical Officer
PSTX

PR Newswire

7 months ago

Poseida Therapeutics Appoints Syed Rizvi, M.D., as Chief Medical Officer

Poseida Therapeutics to Present at H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference
PSTX

PR Newswire

7 months ago

Poseida Therapeutics to Present at H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference

Poseida Therapeutics Announces FDA Orphan Drug Designation Granted to P-BCMA-ALLO1 for the Treatment of Multiple Myeloma
PSTX

PR Newswire

7 months ago

Poseida Therapeutics Announces FDA Orphan Drug Designation Granted to P-BCMA-ALLO1 for the Treatment of Multiple Myeloma

US$14.00 - That's What Analysts Think Poseida Therapeutics, Inc. (NASDAQ:PSTX) Is Worth After These Results
PSTX

Simply Wall St.

7 months ago

US$14.00 - That's What Analysts Think Poseida Therapeutics, Inc. (NASDAQ:PSTX) Is Worth After These Results

Poseida Therapeutics Full Year 2023 Earnings: Beats Expectations
PSTX

Simply Wall St.

7 months ago

Poseida Therapeutics Full Year 2023 Earnings: Beats Expectations

PSTX

GuruFocus.com

8 months ago

Poseida Therapeutics Inc (PSTX) Reports Fourth Quarter and Full Year 2023 Financial Results

Poseida Therapeutics, Inc. (PSTX) Reports Q4 Loss, Tops Revenue Estimates
PSTX

Zacks

8 months ago

Poseida Therapeutics, Inc. (PSTX) Reports Q4 Loss, Tops Revenue Estimates

Poseida Therapeutics Provides Updates and Financial Results for the Fourth Quarter and Full Year 2023
PSTX

PR Newswire

8 months ago

Poseida Therapeutics Provides Updates and Financial Results for the Fourth Quarter and Full Year 2023

Poseida Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
PSTX

PR Newswire

8 months ago

Poseida Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Institutional investors own a significant stake of 41% in Poseida Therapeutics, Inc. (NASDAQ:PSTX)
PSTX

Simply Wall St.

8 months ago

Institutional investors own a significant stake of 41% in Poseida Therapeutics, Inc. (NASDAQ:PSTX)

Investors in GoPro (NASDAQ:GPRO) have unfortunately lost 65% over the last three years
PSTX

Simply Wall St.

9 months ago

Investors in GoPro (NASDAQ:GPRO) have unfortunately lost 65% over the last three years

As investors pile into psychedelics, idealism gives way to pharma economics
PSTX

Associated Press Finance

9 months ago

As investors pile into psychedelics, idealism gives way to pharma economics

Central Pacific Financial Corp. (NYSE:CPF) Q4 2023 Earnings Call Transcript
PSTX

Insider Monkey

9 months ago

Central Pacific Financial Corp. (NYSE:CPF) Q4 2023 Earnings Call Transcript

REGENXBIO Announces Presentations at the 20th Annual WORLDSymposium 2024
PSTX

PR Newswire

9 months ago

REGENXBIO Announces Presentations at the 20th Annual WORLDSymposium 2024

The Logistics Play Set to Transform the Permian Basin
PSTX

Oilprice.com

9 months ago

The Logistics Play Set to Transform the Permian Basin

Tactile Medical to Release Fourth Quarter and Fiscal Year 2023 Financial Results on February 20, 2024
PSTX

GlobeNewswire

9 months ago

Tactile Medical to Release Fourth Quarter and Fiscal Year 2023 Financial Results on February 20, 2024

Is Weakness In Daktronics, Inc. (NASDAQ:DAKT) Stock A Sign That The Market Could be Wrong Given Its Strong Financial Prospects?
PSTX

Simply Wall St.

9 months ago

Is Weakness In Daktronics, Inc. (NASDAQ:DAKT) Stock A Sign That The Market Could be Wrong Given Its Strong Financial Prospects?

Down -14.25% in 4 Weeks, Here's Why You Should You Buy the Dip in CureVac N.V. (CVAC)
PSTX

Zacks

9 months ago

Down -14.25% in 4 Weeks, Here's Why You Should You Buy the Dip in CureVac N.V. (CVAC)

Chuck Royce Reduces Stake in NVE Corp
PSTX

GuruFocus.com

9 months ago

Chuck Royce Reduces Stake in NVE Corp

NVE Corp's Dividend Analysis
PSTX

GuruFocus.com

9 months ago

NVE Corp's Dividend Analysis

Here’s Why Greenlight Decided to Repurchase Viatris (VTRS)
PSTX

Insider Monkey

9 months ago

Here’s Why Greenlight Decided to Repurchase Viatris (VTRS)

Footwear Retailer Stocks Q3 Highlights: Shoe Carnival (NASDAQ:SCVL)
PSTX

StockStory

9 months ago

Footwear Retailer Stocks Q3 Highlights: Shoe Carnival (NASDAQ:SCVL)

2 Network Software Stocks to Buy From a Prospering Industry
PSTX

Zacks

9 months ago

2 Network Software Stocks to Buy From a Prospering Industry

Metals Acquisition Limited Provides Operational Update
PSTX

Business Wire

9 months ago

Metals Acquisition Limited Provides Operational Update

Potbelly (PBPB) Boosts Offerings With Revamped Loyalty Program
PSTX

Zacks

9 months ago

Potbelly (PBPB) Boosts Offerings With Revamped Loyalty Program

8x8, Inc. Schedules Third Quarter Fiscal 2024 Earnings Release and Conference Call
PSTX

Business Wire

9 months ago

8x8, Inc. Schedules Third Quarter Fiscal 2024 Earnings Release and Conference Call

DSW Parent Designer Brands Taps Andrea O’Donnell as Brands President
PSTX

WWD

9 months ago

DSW Parent Designer Brands Taps Andrea O’Donnell as Brands President

Virtus Artificial Intelligence & Technology Opportunities Fund Discloses Sources of Distribution – Section 19(a) Notice
PSTX

Business Wire

9 months ago

Virtus Artificial Intelligence & Technology Opportunities Fund Discloses Sources of Distribution – Section 19(a) Notice

1 Hydrogen Stock to Buy Hand Over Fist and 2 to Avoid
PSTX

Motley Fool

9 months ago

1 Hydrogen Stock to Buy Hand Over Fist and 2 to Avoid

Bowman Consulting Group Ltd CFO Bruce Labovitz Sells 5,000 Shares
PSTX

GuruFocus.com

9 months ago

Bowman Consulting Group Ltd CFO Bruce Labovitz Sells 5,000 Shares

Stitch Fix Announces New Employee Inducement Grant
PSTX

GlobeNewswire

9 months ago

Stitch Fix Announces New Employee Inducement Grant

Regenxbio Inc President and CEO Kenneth Mills Sells 45,000 Shares
PSTX

GuruFocus.com

9 months ago

Regenxbio Inc President and CEO Kenneth Mills Sells 45,000 Shares

Holley Names Philip Dobbs Senior Vice President of Customer Experience Marketing
PSTX

Business Wire

9 months ago

Holley Names Philip Dobbs Senior Vice President of Customer Experience Marketing

8x8 Extends XCaaS Platform AI Capabilities with Real-time Meeting Transcriptions and Smart Summarizations
PSTX

Business Wire

9 months ago

8x8 Extends XCaaS Platform AI Capabilities with Real-time Meeting Transcriptions and Smart Summarizations

Calavo Growers Inc (CVGW) Reports Decline in Annual Net Sales by 18%
PSTX

GuruFocus.com

9 months ago

Calavo Growers Inc (CVGW) Reports Decline in Annual Net Sales by 18%

Why Calavo Growers Stock Dropped Today
PSTX

Motley Fool

9 months ago

Why Calavo Growers Stock Dropped Today

REGENXBIO Announces Positive Interim Data from Phase II AAVIATE® Trial of ABBV-RGX-314 for the Treatment of Wet AMD Using Suprachoroidal Delivery
PSTX

PR Newswire

9 months ago

REGENXBIO Announces Positive Interim Data from Phase II AAVIATE® Trial of ABBV-RGX-314 for the Treatment of Wet AMD Using Suprachoroidal Delivery

Precigen Receives Orphan Drug Designation for PRGN-2012 for the Treatment of Recurrent Respiratory Papillomatosis from the European Commission
PSTX

PR Newswire

9 months ago

Precigen Receives Orphan Drug Designation for PRGN-2012 for the Treatment of Recurrent Respiratory Papillomatosis from the European Commission

Taseko Provides Financing and Construction Update for the Florence Copper Project
PSTX

CNW Group

9 months ago

Taseko Provides Financing and Construction Update for the Florence Copper Project

When Will MoneyLion Inc. (NYSE:ML) Turn A Profit?
PSTX

Simply Wall St.

9 months ago

When Will MoneyLion Inc. (NYSE:ML) Turn A Profit?

GoPro Announces $120,000 'GoPro Line of the Winter' Video Contest for Best Single-Clip Ski + Snowboard Videos
PSTX

PR Newswire

9 months ago

GoPro Announces $120,000 'GoPro Line of the Winter' Video Contest for Best Single-Clip Ski + Snowboard Videos

Invesco Senior Income Trust's Dividend Analysis
PSTX

GuruFocus.com

9 months ago

Invesco Senior Income Trust's Dividend Analysis

Insider Sell: COO Michael Bruen Sells 5,000 Shares of Bowman Consulting Group Ltd
PSTX

GuruFocus.com

9 months ago

Insider Sell: COO Michael Bruen Sells 5,000 Shares of Bowman Consulting Group Ltd

3 Stocks to Buy in the Booming Field of Gene Editing
PSTX

InvestorPlace

9 months ago

3 Stocks to Buy in the Booming Field of Gene Editing

1 Growth Stock Down 96% You'll Regret Not Buying on the Dip in 2024
PSTX

Motley Fool

9 months ago

1 Growth Stock Down 96% You'll Regret Not Buying on the Dip in 2024

Q3 Earnings Review: Footwear Retailer Stocks Led by Boot Barn (NYSE:BOOT)
PSTX

StockStory

9 months ago

Q3 Earnings Review: Footwear Retailer Stocks Led by Boot Barn (NYSE:BOOT)

AVITA Medical Announces Preliminary 2023 Financial Highlights, Provides 2024 Financial Guidance and Business Update
PSTX

GlobeNewswire

9 months ago

AVITA Medical Announces Preliminary 2023 Financial Highlights, Provides 2024 Financial Guidance and Business Update

Strength Seen in Tree.com (TREE): Can Its 22.1% Jump Turn into More Strength?
PSTX

Zacks

9 months ago

Strength Seen in Tree.com (TREE): Can Its 22.1% Jump Turn into More Strength?

Janux Therapeutics Promotes Co-Founder Tommy DiRaimondo, Ph.D. to Chief Scientific Officer
PSTX

Business Wire

9 months ago

Janux Therapeutics Promotes Co-Founder Tommy DiRaimondo, Ph.D. to Chief Scientific Officer

Editas Medicine Highlights 2024 Anticipated Milestones and Strategic Priorities at the J.P. Morgan Healthcare Conference
PSTX

GlobeNewswire

9 months ago

Editas Medicine Highlights 2024 Anticipated Milestones and Strategic Priorities at the J.P. Morgan Healthcare Conference

CardRatings Unveils Its ‘Best Credit Cards of 2024’ List and Annual Cardholder Survey Results
PSTX

Business Wire

10 months ago

CardRatings Unveils Its ‘Best Credit Cards of 2024’ List and Annual Cardholder Survey Results

Avanos Medical, Inc. Reports Preliminary Fourth Quarter and Full-Year 2023 Financial Results; Revises Preliminary 2024 Revenue Outlook
PSTX

PR Newswire

10 months ago

Avanos Medical, Inc. Reports Preliminary Fourth Quarter and Full-Year 2023 Financial Results; Revises Preliminary 2024 Revenue Outlook

Poseida Therapeutics Highlights Recent Progress, Strategic Priorities and Anticipated 2024 Key Milestones
PSTX

PR Newswire

10 months ago

Poseida Therapeutics Highlights Recent Progress, Strategic Priorities and Anticipated 2024 Key Milestones

Could Monro, Inc.'s (NASDAQ:MNRO) Weak Financials Mean That The Market Could Correct Its Share Price?
PSTX

Simply Wall St.

10 months ago

Could Monro, Inc.'s (NASDAQ:MNRO) Weak Financials Mean That The Market Could Correct Its Share Price?

Is Zynex, Inc.'s (NASDAQ:ZYXI) Recent Stock Performance Tethered To Its Strong Fundamentals?
PSTX

Simply Wall St.

10 months ago

Is Zynex, Inc.'s (NASDAQ:ZYXI) Recent Stock Performance Tethered To Its Strong Fundamentals?

The Zacks Analyst Blog Highlights American Public Education, Affirm, Barrett Business Services and 8x8
PSTX

Zacks

10 months ago

The Zacks Analyst Blog Highlights American Public Education, Affirm, Barrett Business Services and 8x8

BBSI vs. PAYX: Which Stock Should Value Investors Buy Now?
PSTX

Zacks

10 months ago

BBSI vs. PAYX: Which Stock Should Value Investors Buy Now?

An Intrinsic Calculation For Janux Therapeutics, Inc. (NASDAQ:JANX) Suggests It's 44% Undervalued
PSTX

Simply Wall St.

10 months ago

An Intrinsic Calculation For Janux Therapeutics, Inc. (NASDAQ:JANX) Suggests It's 44% Undervalued

Northrim (NRIM) is on the Move, Here's Why the Trend Could be Sustainable
PSTX

Zacks

10 months ago

Northrim (NRIM) is on the Move, Here's Why the Trend Could be Sustainable

QuinStreet Inc CFO Gregory Wong Sells 33,010 Shares
PSTX

GuruFocus.com

10 months ago

QuinStreet Inc CFO Gregory Wong Sells 33,010 Shares

Share on Social Networks: